MaxCyte signed a strategic platform license (SPL) with Walking Fish Therapeutics which focuses on B cell-based therapeutics. Walking Fish obtains non-exclusive clinical and commercial rights to use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results